LIST OF DRUG CANDIDATES TARGETING NASH
(updated weekly)

Click on the name of drug to access data sheet 


OCALIVA (OCA), Laboratory : INTERCEPT

Type of drug : FXR Agonist

Clinical trials advancement : Ongoing Phase 3

The drug got the Breakthrough Therapy Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 27


ELAFIBRANOR (GFT505), Laboratory : GENFIT

Type of drug : dual PPAR alpha delta agonist

Clinical trials advancement : Recruiting Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 35


CENICRIVIROC, Laboratory : ALLERGAN

Type of drug : CCR2CCR5 Antagonist

Clinical trials advancement : Recruiting Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 37


SELONSERTIB (GS-4997), Laboratory : GILEAD

Type of drug : (ASK1) inhibitor

Clinical trials advancement : Recruiting Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 36


NALMEFENE (JKB121), Laboratory : TaiwanJPharmaceuticals

Type of drug : Opioid receptor antagonists; Toll-like receptor 4 antagonists

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 87


GR_MD_02, Laboratory : GALECTIN

Type of drug : Galectin Inhibitor

Clinical trials advancement : Ongoing Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 64


BMS986036, Laboratory : Bristol-MyersSquibb

Type of drug : PEG-FGF21

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 87


NGM282, Laboratory : NGMBioPHARM

Type of drug : FGF19 hormon

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 88


ARAMCHOL, Laboratory : GALMED

Type of drug : FABACs

Clinical trials advancement : Ongoing Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 68


MGL_3196, Laboratory : MADRIGAL

Type of drug : THR-β Agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 94


GS9674, Laboratory : GILEAD

Type of drug : FXR agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 97


MSDC_0602, Laboratory : OCTETA

Type of drug : mTOT modulating insulin sensitizer

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 98


LJN452, Laboratory : NOVARTIS

Type of drug : non-BA FXR agonist

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 90


VOLIXIBAT (SHP626), Laboratory : SHIRE

Type of drug : (ASBT) inhibitor

Clinical trials advancement : Recruiting Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 75


IMM124E, Laboratory : IMMURON

Type of drug : anti-LPS antibodies and adjuvants

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 101


EMRICASAN (IDN-6556, PF-03491390), Laboratory : CONATUS

Type of drug : potent inhibitor of caspase-mediated pro-inflammatory cytokines

Clinical trials advancement : Recruiting Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 77


LMB763, Laboratory : NOVARTIS

Type of drug : non-BA FXR agonist

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 94


SEMAGLUTIDE, Laboratory : NOVONORDISK

Type of drug : GLP_1analog

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 108


SAROGLITAZAR, Laboratory : ZYDUS

Type of drug : dual PPAR-α γ agonist

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 103


REMOGLIFOZIN, Laboratory : AVOLYNT

Type of drug : SGLT2 inhibitor

Clinical trials advancement : Initiating Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 88


LANIFIBRANOR (IVA337), Laboratory : INVENTIVA

Type of drug : tri PPAR α δ γ

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 106


GRI_0621, Laboratory : GRIPharma

Type of drug : NKT I Inhibitor

Clinical trials advancement : Analysing Results Phase 2a

Estimated Time to market in months : 112


GS0976, Laboratory : GILEAD

Type of drug : ACC inhibitor

Clinical trials advancement : Ongoing Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 84


VK2809, Laboratory : VIKING

Type of drug : THR-? Agonist prodrug

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 118


MT_3995 (MT-3995), Laboratory : MitsubishiTanabePharma

Type of drug : Aldosterone receptor antagonists

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 118


MN_001 (TIPELUKAST), Laboratory : MEDICINOVA

Type of drug : (5-LOLT) inibitor

Clinical trials advancement : Recruiting Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 97


NITAZOXANIDE, Laboratory : GENFIT

Type of drug : Stellate Cell activation

Clinical trials advancement : Recruiting Phase 2a

Estimated Time to market in months : 121


PF_05221304 (PF_05221304), Laboratory : PFITZER

Type of drug : Acetyl CoA-Carboxylase (ACC) Inhibitor

Clinical trials advancement : Recruiting Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 99


BI_1467335 (BI_1467335 or PXS-4728A), Laboratory : Boehringer_Ingelheim

Type of drug : VAP-1/AOC3 protein inhibitor

Clinical trials advancement : Recruiting Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 97


NAMODENOSON, Laboratory : CANFITE

Type of drug : A3AR Agonist

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


LIK066 (LIK066), Laboratory : NOVARTIS

Type of drug : SGLT1-SGLT2 inhibitor

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


FORALUMAB, Laboratory : TIZIANA

Type of drug : anti-CD3 monoclonal antibody (mAbs)

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


DF102 (AF102), Laboratory : AFIMMUNE

Type of drug : Undefined mechanism

Clinical trials advancement : Initiating Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 99


GEMCABENE, Laboratory : GEMPHIRE

Type of drug : enhance the clearance of VLDLs and may also inhibit ACC

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


KBP_042, Laboratory : NORDICBIOSCIENCE

Type of drug : (DACRA)

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 123


PF_06865571 (PF_06865571), Laboratory : PFITZER

Type of drug : Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 123


PF_06667272 (PF_06667272), Laboratory : PFITZER

Type of drug : Myeloperoxidase Inhibitor

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 123


PF_06835919 (PF_06835919), Laboratory : PFITZER

Type of drug : Ketohexokinase (KHK) Inhibitor

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 124


NGM313, Laboratory : NGMBio

Type of drug : KLB-FGFR1c

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 125


CER_209 (CER_209), Laboratory : CERENIS

Type of drug : P2Y13 receptor agonist

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 127


DUR928 (DUR_928), Laboratory : DURECT

Type of drug : epigenetically-active endogenous small molecule

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 127


NAMACIZUMAB (RYI-018 or JNJ-2463), Laboratory : BIRDROCKBIO

Type of drug : NAMA-CB1

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 127


BMS_986171, Laboratory : Bristol-MyersSquibb

Type of drug : PEG-FGF21

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 127


AZD4076, Laboratory : ASTRAZENECA

Type of drug : miR-103107 inhibitor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 128


RTU_1096, Laboratory : SUCAMPO

Type of drug : Vap-1 inhibitor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 128


ND_L02_s0201, Laboratory : NITTODENKO

Type of drug : (SERPINH1) (Hsp47)

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 128


DRX_065, Laboratory : DeuteRx

Type of drug : stabilized, preferred enantiomer of pioglitazone

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 129


IONIS_DGAT2Rx, Laboratory : IONISPHARMA

Type of drug : DGAT2Rx

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 129


INT_767, Laboratory : INTERCEPT

Type of drug : farnesoid X receptor (FXR) and TGR5, a G-protein coupled bile acid receptor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 131


EDP_305, Laboratory : ENANTA

Type of drug : FXR agonist

Clinical trials advancement : Recruiting Phase 1

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 107


NC_001, Laboratory : NAIAPHARMA

Type of drug : act on insulin resistance

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 134


HEPASTEM, Laboratory : PROMETHERA

Type of drug : human liver derived mesenchymal stem

Clinical trials advancement : Preclinic

Estimated Time to market in months : 135


VK0214, Laboratory : VIKING

Type of drug : TRβ agonist

Clinical trials advancement : Preclinic

Estimated Time to market in months : 135


TGFTX4, Laboratory : GENFIT

Type of drug : ?

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


RLBN1001 (RLBN1001), Laboratory : RELBURN

Type of drug : Bifonctional Urates Inhibitors

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


GKT_137831, Laboratory : GENKYOTEC

Type of drug : NOX1&4 inhibitor

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


RYI_018, Laboratory : CREATIVEBIOLAB

Type of drug : (CB-1)

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


NV556 (NV556), Laboratory : NeuroVivePharmaceuticalAB

Type of drug : mild mitochondrial protonophores

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


NVP022 (NVP022), Laboratory : NeuroVivePharmaceuticalAB

Type of drug : mild mitochondrial protonophores

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


JH_0920 (JH_0920), Laboratory : JOYCEBiotech

Type of drug : inhibit anaerobic metabolism in eukaryotic

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


CB4209-CB4211 (CB4209-CB4211), Laboratory : CohBar

Type of drug : MOTS-c peptide analog

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


VPR_423 (VPR_423), Laboratory : VisionaryPharmaceuticals

Type of drug : RORgammaT

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


The dynamic list is here 



Share on StockTwits
FR-flag

WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE